For all new eyes:
It is apparent that the current human trial for Brilacidin in regards to CV19 is paramount to the success of IPIX, but for those not familiar with the IPIX story let's once again reiterate why Brilacidin is different from EVERY other drug going thru trials today and likely different from any drug EVER to go thru trials and why these differences are what makes every stockholder know that we are sitting on a gold mine with this stock:
1. Brilacidin was conceived by a medical genius, Dr. William DeGrado, who has published over 400 papers, won about every medical award that can be won, is the leading authority on the new arm of medicine that he brought into existence (that of defensin mimetics), and who currently runs his own lab strictly for defensin mimetic studies at the highly acclaimed UCSF, a public research facility associated with the U of CA system. UCSF has no undergraduate programs, every student there is working on advanced degrees and only gets accepted to work on a specific program. So all of Dr. DeGrado's graduates become proponents of his arm of medicine and further exploration of this arm of medicine. Dr. DeGrado is not a medical doctor, he is a phD specializing in pharmaceutical chemistry. This is why he was able to conceptualize the structure of the small molecule that would become Brilacidin.
2. Brilacidin was developed by humans (around 2002) but refined and improved by the closest thing to AI (artificial intelligence) as it spent about 6 years on the super computer (known as Big Ben) in Pittsburgh ramping up its benefits and eliminating its weaknesses which would lead to worrisome side effects. Compare this to all other drugs that went thru labs and one can understand why Brilacidin is seemingly light years ahead of its time.
3. Brilacidin has never failed a clinical trial and it has gone thru a number. It is anti viral, bacterial, fungal, inflammatory, and possesses unique immunotherapeutic properties and ALL of the above features are used to kill CV19. In these prior trials on over 400 patients it was also shown to be well tolerated with no discernible side effects (almost unheard of in todays pharma market, just listen to TV ads for drugs and one sees in most cases the side effects seem as dire as the problem it is supposed to cure).
4. Being that it kills viruses in a completely new way from all prior drugs, viruses cannot build up a resistance to it. Please note that Brilacidin KILLS the CV19 virus, a feature very few, if any, competitive products can claim
5. In testing at government run regional bio labs (RBLs)IPIX had no input as to running the tests or interpreting the results)so all data was derived and published by those RBLs. It was shown to have a Selectivity Index (SI) of 426. This index evaluates the ability for in vitro testing (in a petri dish) to transfer with the same results in human testing. Anything over 100 is considered good and Remsdesivir received about a 129. Thus, it looks like Brilacidin should be a lock on working in humans as effectively as it did in petri dishes and on human tissues. To refresh your memory of human tissue results, Brilacidin killed 97% in lung tissue within a few hours and 85% in kidney tissues within a few hours. The IV being given in the current trial (I believe it is for about 1 hour but not positive) should help raise these numbers IMO as it keeps B in the system a decent amount of time.
6. Brilacidin is made from common materials, does not require special handling (as frigid cold as do other CV drugs/vaccines),is very cost effective compared to other methods, and is currently being developed for a nasal spray or nebulizer (sprayed directly into the lungs via the mouth)as additional delivery systems.
7. Brilacidin was shown to be so effective in the RBL testing that one requested funding for a PANCORONA investigation since it appears that Brilacidin could prove effective against ALL corona viruses to include The Flu and Herpes as just some of the other uses.
8. Brilacidin has yet to meet a bacteria or virus it couldn't kill.
The above points of fact, all derived by non-IPIX sources, should give all stockholders a feeling that what we own is extremely special. Each stockholder must come to their own conclusions as to the point at which they will sell their holdings in iPIX, but all should be aware that though this is currently a penny stock it is not because our products are not worth a FORTUNE and could very well lead to generational wealth in time for those that bet on this company early. I consider .45 still extremely early for all stockholders and hate to think some will be bamboozled to sell way too early and lose out on a possible golden ring stock that comes along only a few times in a lifetime.
